Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $32.69 million. The enterprise value is -$25.30 million.
Important Dates
The last earnings date was Monday, November 16, 2026, after market close.
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 7.26 million shares outstanding. The number of shares has increased by 120.66% in one year.
| Current Share Class | 7.26M |
| Shares Outstanding | 7.26M |
| Shares Change (YoY) | +120.66% |
| Shares Change (QoQ) | +66.57% |
| Owned by Insiders (%) | 7.34% |
| Owned by Institutions (%) | 49.97% |
| Float | 5.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.91 |
| Forward PS | 32.54 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.38, with zero debt.
| Current Ratio | 3.38 |
| Quick Ratio | 3.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,138.92 |
Financial Efficiency
Return on equity (ROE) is -800.39% and return on invested capital (ROIC) is -297.94%.
| Return on Equity (ROE) | -800.39% |
| Return on Assets (ROA) | -417.95% |
| Return on Invested Capital (ROIC) | -297.94% |
| Return on Capital Employed (ROCE) | -289.95% |
| Weighted Average Cost of Capital (WACC) | 19.73% |
| Revenue Per Employee | $1.23M |
| Profits Per Employee | -$7.13M |
| Employee Count | 29 |
| Asset Turnover | 0.72 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Cue Biopharma has paid $500,000 in taxes.
| Income Tax | 500,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.14% in the last 52 weeks. The beta is 2.81, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.81 |
| 52-Week Price Change | -74.14% |
| 50-Day Moving Average | 22.14 |
| 200-Day Moving Average | 21.50 |
| Relative Strength Index (RSI) | 25.08 |
| Average Volume (20 Days) | 1,105,753 |
Short Selling Information
The latest short interest is 862,798, so 11.88% of the outstanding shares have been sold short.
| Short Interest | 862,798 |
| Short Previous Month | 792,553 |
| Short % of Shares Out | 11.88% |
| Short % of Float | 16.25% |
| Short Ratio (days to cover) | 5.12 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $35.64 million and -$206.68 million in losses. Loss per share was -$32.58.
| Revenue | 35.64M |
| Gross Profit | 19.81M |
| Operating Income | -137.81M |
| Pretax Income | -206.18M |
| Net Income | -206.68M |
| EBITDA | -136.50M |
| EBIT | -137.81M |
| Loss Per Share | -$32.58 |
Full Income Statement Balance Sheet
The company has $57.99 million in cash and no debt, with a net cash position of $57.99 million or $7.98 per share.
| Cash & Cash Equivalents | 57.99M |
| Total Debt | n/a |
| Net Cash | 57.99M |
| Net Cash Per Share | $7.98 |
| Equity (Book Value) | 38.40M |
| Book Value Per Share | 4.95 |
| Working Capital | 46.98M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$51.10 million and capital expenditures -$121,000, giving a free cash flow of -$51.23 million.
| Operating Cash Flow | -51.10M |
| Capital Expenditures | -121,000 |
| Depreciation & Amortization | 1.31M |
| Net Borrowing | -1.50M |
| Free Cash Flow | -51.23M |
| FCF Per Share | -$7.05 |
Full Cash Flow Statement Margins
| Gross Margin | 55.58% |
| Operating Margin | -386.69% |
| Pretax Margin | -578.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -120.66% |
| Shareholder Yield | -120.66% |
| Earnings Yield | -723.91% |
| FCF Yield | -157.40% |
Analyst Forecast
The average price target for Cue Biopharma is $68.67, which is 1,426.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $68.67 |
| Price Target Difference | 1,426.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -30.10% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on April 24, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Apr 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |